Beth Fand Incollingo


Cancer May Not Suggest Poor Health Outcomes After COVID-19, Study Shows

November 16, 2020

A retrospective study of patients with COVID-19 showed that those with cancer were not more likely to experience severe symptoms or death due to the virus than those without cancer. Rather, only age and obesity were associated with poor COVID-19 outcomes.

Adding Darzalex to Standard Treatment for High-Risk Multiple Myeloma May Delay Disease Progression

October 27, 2020

A meta-analysis of six clinical trials showed that standard treatment regimens for high-risk multiple myeloma may be more effective at delaying disease progression if they are given in combination with the targeted drug Darzalex (daratumumab).

People Who Have Cancer Can Leave Behind a Couple Kinds of Legacies

October 21, 2020

“The future is not yours,” says Pam Haldeman, who has metastatic breast cancer. “A way to get back a little bit of control is to be your own advocate and get aggressive in researching and going to every conference or retreat available.”

‘Don’t Sugarcoat Things’ When Someone You Know is Diagnosed with Metastatic Breast Cancer

October 21, 2020

“Most kinds of breast cancer are potentially curable, but metastatic breast cancer is not,” says Kathleen Friel, lab director at the Burke Neurological Institute of Weill Cornell Medicine. “People assume, ‘Oh, you must be fine because you look fine.’ It puts a lot of expectations on us that, if somehow we’re strong enough, then we’ll beat this disease.”

Adding Tukysa to Regimen for Metastatic HER2-Positive Breast Cancer Does Not Decrease Quality of Life

October 08, 2020

Adding the targeted drug Tukysa (tucatinib) to Herceptin (trastuzumab) and the chemotherapy Xeloda (capecitabine) lengthens life and time until disease progression in patients, without decreasing their health-related quality of life, researchers found in a follow-up to the HER2CLIMB study.

Ibrance Plus Faslodex in Hormone-Driven Advanced Breast Cancer Delays Disease Progression

October 06, 2020

In a clinical trial, adding the CDK4/6 inhibitor Ibrance (palbociclib) to the hormonal treatment Faslodex (fulvestrant) delayed disease progression in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.

Where is The Balance Between Prostate Cancer Screening and Overtreatment?

October 02, 2020

After a recommendation against routine prostate cancer screening, rates of early disease declined while the incidence of advanced disease rose. The trend highlights the difficult balance between screening and potential overtreatment.

Long-Term Evidence Confirms Benefit of Approved Lynparza Maintenance Strategy in Advanced Ovarian Cancer

September 29, 2020

Five-year follow-up data from the phase 3 SOLO-1 trial demonstrates a nearly five-year delay in disease progression with Lynparza compared with a delay of just over a year with placebo in women with newly diagnosed, advanced ovarian cancer harboring a BRCA gene mutation.

FDA Updates Breast Implant Labeling Recommendations to Help Inform Patients About Dangerous Potential Side Effects

September 29, 2020

New guidance from the Food and Drug Administration recommends that the makers of breast implants include a black-box warning, a patient decision checklist and other information on product labels that will help protect them against a cancer and an autoimmune condition that can arise from use of the devices.